Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
28 Results for "
EphB4
" in MedChemExpress (MCE) Product Catalog:
Products (28)
28 Results for "EphB4" in MCE Product Catalog:
9
9 Publications Verification
Synonyms: BHG712
Target:
Research Areas:
NVP-BHG712 is an oral active EphB4 kinase autophosphorylation inhibitor, with IC50 values of 3.3 nM and 3.0 nM for EphA2 and EphB4, respectively .
2
2 Cited Publications
Target:
Research Areas:
NVP-BHG712 isomer, a regioisomer of NVP-BHG712, shows conserved non-bonded binding to EPHA2 and EPHB4 .
Cat. No.: HY-16265
CAS No.: 900573-88-8
Target:
Research Areas:
JI-101 is an orally active multi-kinase inhibitor. JI-101 inhibits EphB4, VEGFR-2 and PDGFR-β. JI-101 exhibits anticancer activity. JI-101 can be used in research related to ovarian cancer .
Cat. No.: HY-RS04436
Target:
Research Areas:
EPHB4 Human Pre-designed siRNA Set A contains three designed siRNAs for EPHB4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Target:
Research Areas:
AZ12672857 is an orally active inhibitor of EphB4 (IC50=1.3 nM) and Src kinases. AZ12672857 shows good inhibition of proliferation of c-Src transfected 3T3 cells (IC50=2 nM) as well as autophosphorylation of EphB4 in transfected CHO-K1 cells (IC50=9 nM) .
Cat. No.: HY-P990406
Target:
Research Areas:
Cat. No.: HY-15268
CAS No.: 1092787-12-6
PP487 is a selective dual inhibitor of Tyrosine kinase/PI3-K, with IC50 values of 0.017 μM, 0.072 μM, 0.004 μM, 0.01 μM, 0.55 μM, 0.22 μM, and < 0.01 μM against DNA-PK, mTOR, Hck, Src, EGFR, EphB4, and PDGFR, respectively. PP487 can be used in cancer research .
Cat. No.: HY-RS24229
Target:
Research Areas:
Ephb4 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ephb4 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-186005
CAS No.: 633281-74-0
Target:
Research Areas:
EPHB4 modulator-1 is a EPHB4 modulator.
Cat. No.: HY-RS17762
Target:
Research Areas:
Ephb4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ephb4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-155684
CAS No.: 3058085-76-7
Target:
Research Areas:
SA-PA is an intracellular self-assembled PROTAC based on azide and alkyne. SA-PA is able to selectively degrade VEGFR-2, PDGFR-β and EphB4 proteins in U87 cells. SA-PA can be converted to PROTAC in situ by click reaction with the help of endogenous copper in tumor tissues .
Cat. No.: HY-185227
CAS No.: 1394837-94-5
Target:
Research Areas:
EphB4-IN-1 is a selective EphB4 tyrosine kinase inhibitor with IC50 values of 0.16-0.30 μM. EphB4-IN-1 binds to the ATP binding site of EphB4 in a DFG-in conformation, forming four stable intermolecular hydrogen bonds. EphB4-IN-1 also inhibits Src, Abl1, Lck, and EGFR kinases. EphB4-IN-1 inhibits EphB4 autophosphorylation. EphB4-IN-1 can be used for the research of cancer, such as non small cell lung cancer .
Cat. No.: HY-N3634
CAS No.: 775351-91-2
Target:
Cat. No.: HY-10654
CAS No.: 1192216-03-7
Target:
Research Areas:
EphB4-IN-2 is a tyrosine kinase inhibitor targeting the Eph family and Src family. EphB4-IN-2 binds to the ATP-binding site of the kinase domain of EphB4, and exhibits high affinity for tyrosine kinases with threonine as the gatekeeper residue, such as Abl, Lck and Src. EphB4-IN-2 can be used in research related to tumor-associated angiogenesis .
Cat. No.: HY-155685
CAS No.: 3058085-77-8
Target:
Research Areas:
SA-VA is an intracellular self-assembled PROTAC based on azide and alkyne. SA-VA is able to selectively degrade VEGFR-2 and EphB4 proteins in U87 cells. SA-VA can be converted to PROTAC in situ by click reaction with the help of endogenous copper in tumor tissues. SA-VA promotes apoptosis and blocks cells in S phase .
Cat. No.: HY-171217
CAS No.: 867330-68-5
Target:
Research Areas:
TG-100435 is a multitargeted, orally active protein tyrosine kinase inhibitor, with Ki of 13 to 64 nM for Src, Lyn, Abl, Yes, Lck, and EphB4. TG-100435 plays an important role in cancer research .
Cat. No.: HY-P77646
Purity: ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: EphB4; Tyrosine-Protein Kinase Receptor HTK; Prev. HTK; Ephrin Receptor EphB4; Hepatoma Transmembrane Kinase; CMAVM2; Ephrin Type-B Receptor 4; LMPHM7; Tyro11; TYRO11; Tyrosine-Protein Kinase TYRO11; EphB4; MYK1; HFASD; EPH Receptor B4; Receptor Protein-T
Cat. No.: HY-P73005
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: EphB4; Tyrosine-Protein Kinase Receptor HTK; Prev. HTK; Ephrin Receptor EphB4; Hepatoma Transmembrane Kinase; CMAVM2; Ephrin Type-B Receptor 4; LMPHM7; Tyro11; TYRO11; Tyrosine-Protein Kinase TYRO11; EphB4; MYK1; HFASD; EPH Receptor B4; Receptor Protein-T
Cat. No.: HY-P74171
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: EphB4; Tyrosine-Protein Kinase Receptor HTK; Prev. HTK; Ephrin Receptor EphB4; Hepatoma Transmembrane Kinase; CMAVM2; Ephrin Type-B Receptor 4; LMPHM7; Tyro11; TYRO11; Tyrosine-Protein Kinase TYRO11; EphB4; MYK1; HFASD; EPH Receptor B4; Receptor Protein-T
Cat. No.: HY-P73002
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: EphB4; Tyrosine-Protein Kinase Receptor HTK; Prev. HTK; Ephrin Receptor EphB4; Hepatoma Transmembrane Kinase; CMAVM2; Ephrin Type-B Receptor 4; LMPHM7; Tyro11; TYRO11; Tyrosine-Protein Kinase TYRO11; EphB4; MYK1; HFASD; EPH Receptor B4; Receptor Protein-T
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
